J&J’s Caplyta succeeds in 2nd phase 3 bipolar mania trial
Caplyta, a Johnson & Johnson drug, met its primary and key secondary endpoints in a second pivotal phase 3 trial evaluating it for manic episodes in adults with bipolar I disorder. Study 452 found that Caplyta significantly reduced manic symptoms and overall illness severity compared with placebo at Week 3, with improvements observed as early […] The post J&J’s Caplyta succeeds in 2nd phase 3 bipolar mania trial appeared first on Becker's Hospital Review | Healthcare News &...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.